Skip to content

The Effect of Neurontin on Pain Management in the Acutely Burned Patient

The Effect of Neurontin on Pain Management in the Acutely Burned Patient

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01265056
Enrollment
53
Registered
2010-12-22
Start date
2010-02-28
Completion date
2011-09-30
Last updated
2018-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burn Injury, Pain

Brief summary

Burn patients have extreme pain. Opioids are the main agents used for analgesia. We therefore propose a single center study to fruther assess the efficacy of neuropathic agents in controlling the pain associated with acute thermal injury.

Detailed description

The study was conducted in a 16-bed American Burn Association certified burn unit. Patients age \>18 years old, with at least a 5% burn injury and an expected length of stay (LOS) of 48 hours, were approached for enrollment in this prospective, placebo controlled randomized study. Patients who were pregnant, lactating, prisoners or who had renal insufficiency were excluded. After consent, patients were assigned to either placebo or Gp by random numbers generated in Microsoft Excel (2010). Both the drug and the placebo were over-encapsulated to appear identical. The placebo pills contained starch. The research clinical pharmacist was the only unblinded staff member and did not participate in clinical care of the patients. Following randomization, patients received a loading dose of study drug on day one and began three times a day (TID) dosing per the dose escalation schedule the following day. At discharge, patients were given a three day taper per the dose de-escalation schedule Patients were assessed for completion of psychosocial adjustment (Brief Symptom Inventory, BSI, and Sickness Inventory Profile, SIP) at their first clinic visit. Agents used for pain control included: acetaminophen, non-steroidal anti-inflammatories, morphine instantaneous release and morphine extended release. In the case of allergies or ineffectiveness, other agents were occasionally used. Short acting morphine was ordered every two hours prn and hydromorphone was ordered every four hours as needed. All were converted to morphine equivalents. The study was powered to detect a 22% difference in opioid consumption between the two groups based on the work by Cuignet et al. It was estimated that a total of 50 patients were needed to achieve an alpha of 0.05 and a beta of 0.80 to detect the difference in the primary endpoint. For statistical purposes, conversion tables were used to convert all opioid medications into morphine equivalents with 1 morphine equivalents (ME)=30mg oral morphine. The primary outcome variable (morphine consumption) were adjusted for days past injury. The BSI and SIP scales were scored according to study directions. Both an intention to treat and actual treatment analysis were performed using Stata 11.2 for Windows (Stata Corp. College Station, Texas, U.S.A.). Continuous variables between groups were analyzed with the students T test. Categorical variables were analyzed with the Chi Square test or Fischer Exact Test where appropriate. A random effects model adjusting for confounders was used to assess the effect of treatment on the outcome measures. The study was approved by the University's Institutional Review Board and was registered with the clinical trials association (200909736).

Interventions

DRUGGabapentin

On Study day 1: 1200mg (single dose). Study day 2,3: 300mg TID, 900mg daily. Study day 4-7: 600mg TID 1800mg\* daily. Study day 8-11: 800mg TID 2400mg\* daily \[Optional increase to 2400 if pain scores are still 4 on NRS\] Study day 11: 1200mg TID 3600mg\* daily \[Optional increase to 3600 if pain scores are still \>4 on NRS\] \* May revert back to prior dose if adverse symptoms occur and are thought to be drug related. Up titration then will be preformed in 48 hours following deexcalation.

DRUGPlacebo

Sugar Pill is administered similar to the protocol used for the investigational drug.

Sponsors

Lucy A Wibbenmeyer
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Masking description

Participant, Care Provider and Investigator are all masked.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All admitted patients with LOS expected to be \> 48 hours (usually burn injury \> 5%) * \> 18 years of age * Thermal injury to skin

Exclusion criteria

* Prisoners * Pregnant or nursing women * Children \<18 years of age * Frostbite or non thermal injury to skin * Renal insuffiency (creatinine clearance \< 60mL/min) or failure (on renal replacement) * Expected length of stay \< 48 hours (this usually includes burn \<5%

Design outcomes

Primary

MeasureTime frame
Opioid Consumption Between the Treatment and the Control Groups (Morphine Equivalents)From time of enrollment to 2 weeks after being discharged

Secondary

MeasureTime frameDescription
Psychological Functioning as Evaluated by the Brief Symptom Inventory (BSI) Between Treatment and Placebo GroupsFirst Clinic Follow Up After DischargeThe Brief Symptom Inventory 18 (BSI 18) is designed with reliability in mind. The BSI 18 assessment gathers patient-reported data to help measure psychological distress and psychiatric disorders in medical and community populations. As the latest in an integrated series of test instruments that include the SCL-90-R®, BSI® (53 questions), and DPRS® instruments, the BSI 18 test offers a more effective, easy-to-administer tool to help support clinical decision-making and monitor progress throughout treatment. BSI-18 measures three dimensions with 6 questions a piece (somatization , depression , anxiety) and overall psychological distress scores (Global severity index, GSI). Each of the 18 items range from a score of 0-4; total score ranges from 0-72 with higher scores indicating worse function. The GSI score is calculated as the mean of the three subscales. The study reported the GSI score. Higher score is worse.
Difference in Psychological Outcomes on the Sickness Inventory Profile (SIP)First Clinic Follow Up After DischargeThe sickness inventory profile (SIP) is a behaviorally based measure of health status. Scores range from 0-68 with higher numbers indicating worse outcomes. The study report total SIP score. The higher the score the worse the function.

Countries

United States

Participant flow

Recruitment details

Recruitment period 1/2010 to 9/13/2011. Patients were recruited for the study if they met criteria and were admitted for burn injuries.

Pre-assignment details

There were no significant events or approaches following enrollment. Patients were randomized into groups.

Participants by arm

ArmCount
Sugar Pill
Patients in this group received a sugar pill which looked identical to gabapentin.
26
Gabapentin
Patients in this group received gabapentin which looked just like the sugar pill.
27
Total53

Withdrawals & dropouts

PeriodReasonFG000FG001
Follow upLost to Follow-up73
Initial Study PeriodWithdrawal by Subject11

Baseline characteristics

CharacteristicGabapentinSugar PillTotal
Age, Categorical
<=18 years
1 Participants0 Participants1 Participants
Age, Categorical
>=65 years
2 Participants1 Participants3 Participants
Age, Categorical
Between 18 and 65 years
24 Participants25 Participants49 Participants
Age, Continuous42.9 years
STANDARD_DEVIATION 11.6
40.6 years
STANDARD_DEVIATION 14.3
41.8 years
STANDARD_DEVIATION 12.9
Region of Enrollment
United States
27 participants26 participants53 participants
Sex: Female, Male
Female
4 Participants2 Participants6 Participants
Sex: Female, Male
Male
23 Participants24 Participants47 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 260 / 27
serious
Total, serious adverse events
0 / 260 / 27

Outcome results

Primary

Opioid Consumption Between the Treatment and the Control Groups (Morphine Equivalents)

Time frame: From time of enrollment to 2 weeks after being discharged

Population: This was an intention to treate analysis. We measured the oral morphine equivalents both groups were administered.

ArmMeasureValue (MEAN)Dispersion
PlaceboOpioid Consumption Between the Treatment and the Control Groups (Morphine Equivalents)7.0 morphine equivalentsStandard Deviation 8.4
GabapentinOpioid Consumption Between the Treatment and the Control Groups (Morphine Equivalents)6.7 morphine equivalentsStandard Deviation 11.6
p-value: <0.05t-test, 2 sided
p-value: <0.04Regression, Logistic
Secondary

Difference in Psychological Outcomes on the Sickness Inventory Profile (SIP)

The sickness inventory profile (SIP) is a behaviorally based measure of health status. Scores range from 0-68 with higher numbers indicating worse outcomes. The study report total SIP score. The higher the score the worse the function.

Time frame: First Clinic Follow Up After Discharge

ArmMeasureValue (MEAN)Dispersion
PlaceboDifference in Psychological Outcomes on the Sickness Inventory Profile (SIP)34.9 units on a scaleStandard Deviation 15.7
GabapentinDifference in Psychological Outcomes on the Sickness Inventory Profile (SIP)36.0 units on a scaleStandard Deviation 19.5
p-value: 0.8t-test, 2 sided
Secondary

Psychological Functioning as Evaluated by the Brief Symptom Inventory (BSI) Between Treatment and Placebo Groups

The Brief Symptom Inventory 18 (BSI 18) is designed with reliability in mind. The BSI 18 assessment gathers patient-reported data to help measure psychological distress and psychiatric disorders in medical and community populations. As the latest in an integrated series of test instruments that include the SCL-90-R®, BSI® (53 questions), and DPRS® instruments, the BSI 18 test offers a more effective, easy-to-administer tool to help support clinical decision-making and monitor progress throughout treatment. BSI-18 measures three dimensions with 6 questions a piece (somatization , depression , anxiety) and overall psychological distress scores (Global severity index, GSI). Each of the 18 items range from a score of 0-4; total score ranges from 0-72 with higher scores indicating worse function. The GSI score is calculated as the mean of the three subscales. The study reported the GSI score. Higher score is worse.

Time frame: First Clinic Follow Up After Discharge

ArmMeasureValue (MEAN)Dispersion
PlaceboPsychological Functioning as Evaluated by the Brief Symptom Inventory (BSI) Between Treatment and Placebo Groups9 units on a scaleStandard Deviation 7.5
GabapentinPsychological Functioning as Evaluated by the Brief Symptom Inventory (BSI) Between Treatment and Placebo Groups7.3 units on a scaleStandard Deviation 7.2
p-value: <0.8t-test, 2 sided

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026